MDT-AP-3189
Med · Medulloblastoma
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- Med
- cancer_type_detailed
- —
- subtype
- Medulloblastoma
- cancer_type
- Med
- subtype
- Medulloblastoma
- overall_survival_months
- 129.48
- os_event
- false
- age_years
- 33.66
- sex
- M
- new_clusters
- S1
- umap1_2d
- -0.828430093
- umap2_2d
- -11.49474491
- umap1_3d
- -1.542758488
- umap2_3d
- -1.181921119
- umap3_3d
- 4.132558517
- dataset
- Med-Taylor
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.350
- PANCREAS_BETA_CELLS+0.200
- SPERMATOGENESIS+0.150
- APICAL_SURFACE+0.030
- WNT_BETA_CATENIN_SIGNALING+0.020
- HEDGEHOG_SIGNALING+0.000
- MYOGENESIS+0.000
- BILE_ACID_METABOLISM-0.030
- E2F_TARGETS-0.080
- COAGULATION-0.090
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.530
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.510
- PROTEIN_SECRETION-0.490
- MTORC1_SIGNALING-0.480
- UNFOLDED_PROTEIN_RESPONSE-0.470
- TGF_BETA_SIGNALING-0.460
- UV_RESPONSE_UP-0.450
- INTERFERON_ALPHA_RESPONSE-0.430
- HEME_METABOLISM-0.410
- INTERFERON_GAMMA_RESPONSE-0.400
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG189 | — | — | 0.956 |
| 2 | ERR4976613 | — | D | 0.954 |
| 3 | msclc569389_S35.txt | — | cohortMD1 | 0.952 |
| 4 | MNG555 | — | — | 0.950 |
| 5 | SRR650204 | — | — | 0.947 |
| 6 | SRR934787 | — | — | 0.946 |
| 7 | ERR4976615 | — | D | 0.946 |
| 8 | MNG598 | — | — | 0.946 |
| 9 | MNG560 | — | — | 0.945 |
| 10 | MNG226 | — | — | 0.944 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 5 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.350 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.200 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.150 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.030 | Temsirolimus | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.020 | Inavolisib | — uncovered |